Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001065514 | SCV001230473 | uncertain significance | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2019-12-19 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant disrupts the p.Ser181 amino acid residue in GALT. Other variant(s) that disrupt this residue have been observed in individuals with GALT-related conditions (PMID: 23022339, 17041746), which suggests that this may be a clinically significant amino acid residue. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C15"). This variant has been observed in individual(s) with biochemical features of galactosemia (Invitae). This variant is not present in population databases (ExAC no frequency). This sequence change replaces serine with tyrosine at codon 181 of the GALT protein (p.Ser181Tyr). The serine residue is highly conserved and there is a large physicochemical difference between serine and tyrosine. |